AbbVie Inc. (ABBV) vs Eli Lilly and Company (LLY)
AbbVie Inc. and Eli Lilly and Company are both Drug Manufacturers General companies. Eli Lilly and Company is the larger, with a market value of $1.11T against $467.4B — 2.4× the size. Eli Lilly and Company trades at the lower P/E: 39.7× against 74.7×. Eli Lilly and Company grew revenue faster over the last twelve months: 49.6% against 10.4%. Eli Lilly and Company has the higher net margin (33.5% vs 9.74%) and the higher return on invested capital (26.3% vs 18.1%). Both pay a dividend; AbbVie Inc. yields more (3.57% vs 0.72%). Across the 22 metrics below, Eli Lilly and Company leads on 14 and AbbVie Inc. on 8.
Valuation
Profitability
| Metric | ABBV | LLY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 71.48% | 83.40% | 72.77% |
| Operating margin | 26.20% | 42.22% | 18.90% |
| Net margin | 9.74% | 33.53% | 8.27% |
| Free cash flow margin | 28.28% | 22.83% | 17.25% |
| Return on equity | (208.10%) | 102.29% | 6.97% |
| Return on assets | 4.61% | 21.97% | 2.76% |
| Return on invested capital | 18.07% | 26.33% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack